Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN EXTENDED RELEASE versus FLOXIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN EXTENDED RELEASE versus FLOXIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
CIPROFLOXACIN EXTENDED RELEASE vs FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
Of course, I can help you with that. However, I must clarify that there is no drug called "FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER". "Floxin" is a brand name for ofloxacin, an antibiotic. Ofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and transcription.
500-1000 mg orally once daily for 7-14 days; extended-release tablet must be taken whole with a meal.
400 mg (as ofloxacin) intravenously every 12 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life approximately 11 hours, ranging from 10-14 hours in patients with normal renal function. Prolonged in renal impairment; requires dose adjustment.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment (up to 30 hours in severe cases).
Primarily renal excretion (50-70% unchanged drug via glomerular filtration and tubular secretion); 15-25% metabolized; 20-35% fecal elimination via biliary secretion and intestinal epithelium.
Primarily renal (80-90% unchanged); biliary/fecal <4%.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic